Use the collections feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
RANDOMIZED CONTROLLED TRIAL
Kazuaki Kaitani, Koichi Inoue, Atsushi Kobori, Yuko Nakazawa, Tomoya Ozawa, Toshiya Kurotobi, Itsuro Morishima, Fumiharu Miura, Tetsuya Watanabe, Masaharu Masuda, Masaki Naito, Hajime Fujimoto, Taku Nishida, Yoshio Furukawa, Takeshi Shirayama, Mariko Tanaka, Katsunori Okajima, Takenori Yao, Yasuyuki Egami, Kazuhiro Satomi, Takashi Noda, Koji Miyamoto, Tetsuya Haruna, Tetsuma Kawaji, Takashi Yoshizawa, Toshiaki Toyota, Mitsuhiko Yahata, Kentaro Nakai, Hiroaki Sugiyama, Yukei Higashi, Makoto Ito, Minoru Horie, Kengo F Kusano, Wataru Shimizu, Shiro Kamakura, Takeshi Morimoto, Takeshi Kimura, Satoshi Shizuta
AIMS: Substantial portion of early arrhythmia recurrence after catheter ablation for atrial fibrillation (AF) is considered to be due to irritability in left atrium (LA) from the ablation procedure. We sought to evaluate whether 90-day use of antiarrhythmic drug (AAD) following AF ablation could reduce the incidence of early arrhythmia recurrence and thereby promote reverse remodelling of LA, leading to improved long-term clinical outcomes. METHODS AND RESULTS: A total of 2038 patients who had undergone radiofrequency catheter ablation for paroxysmal, persistent, or long-lasting AF were randomly assigned to either 90-day use of Vaughan Williams class I or III AAD (1016 patients) or control (1022 patients) group...
February 14, 2016: European Heart Journal
1
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
